Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.22.1
Consolidated Balance Sheets - USD ($)
Feb. 28, 2022
Nov. 30, 2021
Current Assets    
Cash and cash equivalents $ 2,144,631 $ 8,263,088
Marketable securities 472,369 75,412
Accounts receivable (net of allowance for doubtful accounts of $3,126,474 and $3,078,439, respectively) 5,151,565 5,253,173
Prepaid expenses 537,726 558,413
Inventory, current portion 927,568 921,213
Other current assets 483,542 711,208
Total current assets 9,717,401 15,782,507
Property and Equipment-net 3,804,823 3,230,204
Other Assets    
Duke license agreement 14,411,608 14,651,802
Intangible assets, net 1,535,597 1,559,693
Inventory, net of current portion 9,655,372 9,695,363
Goodwill 1,941,411 1,941,411
Deferred tax assets 12,010,133 12,010,133
Operating lease right-of-use asset 839,889 916,493
Deposits and other assets, net 584,064 566,470
Total other assets 41,286,074 41,649,365
Total assets 54,808,298 60,662,076
Current Liabilities    
Accounts payable 1,847,733 1,489,774
Accrued expenses 2,103,953 3,057,386
Note payable 1,129,454 1,898,065
Current portion of operating lease liability 315,860 312,067
Current portion of Duke license agreement liability 1,933,004 4,957,591
Deferred revenue 9,057,085 9,358,696
Total current liabilities 16,387,089 21,073,579
Other Liabilities    
Deferred revenue, net of current portion 32,153,053 31,274,214
Contingent consideration 610,938 727,371
Operating lease long-term liability 530,941 610,989
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 34,169,932 35,404,183
Total liabilities 50,557,021 56,477,762
Commitments and contingencies (Note 12) 0 0
Stockholders' equity    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,675,772 issued and 8,490,898 outstanding as of February 28, 2022 and 14,665,772 issued and 8,557,326 outstanding as of November 30, 2021) 146,758 146,658
Additional paid-in capital 41,650,379 41,586,583
Treasury stock, at cost (21,641,714) (20,812,734)
Accumulated deficit (15,904,146) (16,736,193)
Total stockholders' equity 4,251,277 4,184,314
Total liabilities and stockholders' equity 54,808,298 60,662,076
Series A Junior Participating Preferred Stock [Member]    
Stockholders' equity    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 308,000
Duke University [Member]    
Other Liabilities    
Duke license agreement liability   $ 1,916,609